Ground News

News from Drug Discovery and Development

Stay current with all the latest and breaking news from Drug Discovery and Development. Compare headlines and media bias behind news outlets on stories breaking today.

We’ve discovered 54 headlines written by Drug Discovery and Development during the past 3 months.

Drug Discovery and Development’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Drug Discovery and Development’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Drug Discovery and Development

Where is Drug Discovery and Development located?Drug Discovery and Development's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Drug Discovery and Development News

Robert F. Kennedy Jr. · United States

RFK Jr. removes all members of CDC panel advising U.S. on vaccines

52% Center coverage: 151 sources

Health and Human Services Secretary Robert F. Kennedy Jr. on Monday said he is “retiring” all 17 members of a crucial government panel of vaccine advisors. “A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy said in an opinion piece in the Wall Street Journal on Monday. See the Story

Merck · United States

FDA Approves Merck’s Enflonsia to Prevent RSV in Infants

51% Center coverage: 37 sources

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial virus, or RSV, a common but potentially serious seasonal illness.The drug, Enflonsia, is a long-acting monoclonal antibody intended to prevent RSV-related lower respiratory tract disease in newborns and infants entering their first RSV season.RSV is a leading cause of hospitalization among infants in the United States, espec…See the Story

Bernie Sanders · United States

It’s Harder for Americans to Get Access to Prescription Drugs, Even with Insurance, Research Shows

82% Center coverage: 11 sources

It’s harder for Americans to get access to prescription drugs, even with insurance, research shows For Americans navigating the pharmacy counter, the price of a prescription is often just the beginning of the story. Behind that cost lies an increasingly complex—and often opaque—network of coverage decisions that determine which medications are available and under what conditions. New data from GoodRx Research reveals just how inadequate and rest…See the Story

Dupixent® (Dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic ...

100% Center coverage: 3 sources

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints See the Story

'Definite Conflicts of Interest here:' Expert Discusses New Vaccine Advisory Panel Members

67% Center coverage: 9 sources

This week Health Secretary Robert F. Kennedy Jr. dismissed all 17 members of a CDC committee that advises the agency on vaccine safety and schedules, quickly replacing them with a panel of eight new appointees.New appointees include Dr. Robert Malone, a close Kennedy adviser who during the pandemic promoted unproven COVID-19 treatments and shared conspiracy theories about the origins of the virus.And they include epidemiologist Dr. Martin Kulldo…Robert F. Kennedy Jr. · United States See the Story

Accelerating science with AI-enhanced cryo-EM workflows - Drug Discovery and Development

One of the overlooked areas where artificial intelligence (AI) and machine learning (ML) are showing promise is in life sciences instrumentation. Clearly, AI/ML models hold enormous potential for increasing the speed, accuracy and reliability of drug development, disease research and more. Although use cases for AI vary across the pharmaceutical industry, 59% of pharma and… The post Accelerating science with AI-enhanced cryo-EM workflows appear…Artificial Intelligence Read Article

Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery

Open the article to view the coverage from Intelligence360 NewsCambridge, Massachusetts · Cambridge See the Story

How IQVIA's multi-agent AI 'dream team' aims to rewrite the clinical trial rulebook

2025 was predicted to be the “year of the agent,” referring to the AI technology that can perform autonomous tasks on behalf of a user. And the trends are lining up. “I think agents are already here,” said Raja Shankar, IQVIA’s vice president, machine learning. With adoption gaining ground in retail, financial services, customer service,… The post Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials appeared f…Artificial Intelligence Read Article

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold

A team from MIT CSAIL, the Jameel Clinic, and Recursion has released Boltz-2, an open-source biomolecular model that performs physics-level protein-ligand affinity predictions in approximately 18 seconds on a single consumer GPU. This task previously required hours or days on cluster hardware, often costing upwards of $100 per molecule. By releasing the model, weights, and… The post Open-source Boltz-2 can speed binding-affinity predictions 1,00…Cambridge, Massachusetts · Cambridge See the Story

FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades

The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.United States · United States See the Story

The 2025 Drug Discovery & Development Pharma 50 Report: Deep Dives - Drug Discovery and Development

Oncology tops $84B, Mounjaro surges 124%: Your guide to the 2025 pharma landscape. FY2024 reset the competitive landscape in pharma. While oncology held its top sales standing, the rapid ascent of GLP-1s, market erosion from Humira biosimilars, and the advance of new modalities revised the new biopharma hierarchy. This deep-dive report builds on the Pharma… The post The 2025 Drug Discovery & Development Pharma 50 Report: Deep Dives appeared firs…Read Article

News from Drug Discovery and Development

News from Drug Discovery and Development

Information about Drug Discovery and Development

Media Bias Ratings

Factuality

Ownership

Top Drug Discovery and Development News

RFK Jr. removes all members of CDC panel advising U.S. on vaccines

FDA Approves Merck’s Enflonsia to Prevent RSV in Infants

It’s Harder for Americans to Get Access to Prescription Drugs, Even with Insurance, Research Shows

Dupixent® (Dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic ...

'Definite Conflicts of Interest here:' Expert Discusses New Vaccine Advisory Panel Members

Accelerating science with AI-enhanced cryo-EM workflows - Drug Discovery and Development

Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery

How IQVIA's multi-agent AI 'dream team' aims to rewrite the clinical trial rulebook

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold

FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades

The 2025 Drug Discovery & Development Pharma 50 Report: Deep Dives - Drug Discovery and Development

Similar News Topics

Topics Most Covered by Drug Discovery and Development

Sources Covering Similar Topics

Breaking News Topics Related to Drug Discovery and Development